Study of two new drugs for certain B-cell lymphomas
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a combination of two newer drugs can help people with certain types of B-cell lymphoma that have come back or not responded to treatment. The drugs target cancer cells differently than older treatments, possibly offering a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of B-cell lymphoma, such as transformed large B-cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or marginal zone lymphoma (MZL).
- Your lymphoma has either come back or not responded to at least one previous treatment.
- You are reasonably physically active (able to do light activities).
- Your organs (liver, kidneys, heart, bone marrow) are functioning well enough, as determined by blood tests and other checks.
- You have not been treated with a non-covalent BTK inhibitor (a specific type of targeted therapy) before.
- You are not currently taking immune checkpoint inhibitors (another type of cancer treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a new drug called pirtobrutinib combined with standard chemotherapy (R-CHOP) for people with a type of large B-cell lymphoma that hasn't been treated before. The goal is to see if adding this drug helps the treatment work better.
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
This trial tests two drugs, pirtobrutinib and epcoritamab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after at least one previous treatment. The goal is to see if this combination can help control the disease.
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
This trial tests a new targeted therapy (pirtobrutinib) combined with standard chemo-immunotherapy, with or without an extra targeted drug (polatuzumab vedotin), for people whose large B-cell lymphoma has returned or not responded after prior BTK inhibitor treatment. The goal is to see if this combination can help control the cancer.
Hear when a new Richter Transformation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.